Using monoclonal antibodies to stimulate antitumor cellular immunity

Expert Review of Vaccines

Volumn 10, Issue 7, 2011, Pages 1093-1106

  Durrant, Lindy G ^a   Pudney, Victoria A ^a   Spendlove, Ian ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

antitumor immunity; cancer vaccines; costimulatory molecules; monoclonal antibodies; T cells

Indexed keywords

ABAGOVOMAB; ACID PHOSPHATASE PROSTATE ISOENZYME; ALEMTUZUMAB; CANCER VACCINE; CETUXIMAB; CP 870893; DACARBAZINE; DACETUZUMAB; DNA VACCINE; EPITOPE; FC RECEPTOR IIA; FC RECEPTOR IIB; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IDIOTYPIC ANTIBODY; IMMUNOBODY; IPILIMUMAB; MANNOSE RECEPTOR; MELANOMA VACCINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 105AD7; PROVENGE; RACOTUMOMAB; RITUXIMAB; SCIB 1; TEMOZOLOMIDE; TGN 1412; TICILIMUMAB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; URELUMAB;

ADULT RESPIRATORY DISTRESS SYNDROME; ADVANCED CANCER; ANEMIA; ANTIBODY RESPONSE; ANTIBODY STRUCTURE; ANTIGEN ANTIBODY COMPLEX; ANTIGEN PRESENTATION; BREAST CANCER; CANCER IMMUNIZATION; CANCER SURVIVAL; CARDIOGENIC SHOCK; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONJUNCTIVITIS; CROSS PRESENTATION; CYTOKINE RELEASE SYNDROME; CYTOKINE STORM; DENDRITIC CELL; DIARRHEA; DISSEMINATED INTRAVASCULAR CLOTTING; DNA IMMUNIZATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DOSE ESCALATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ELECTROPORATION; ERYTHEMA; HEADACHE; HUMAN; HYPOTENSION; IMMUNOSTIMULATION; KIDNEY CANCER; KIDNEY FAILURE; LEUKEMIA; LUNG INFILTRATE; LUNG INJURY; LYMPHOCYTOPENIA; MAXIMUM TOLERATED DOSE; MELANOMA; MONOCYTOPENIA; NAUSEA; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHAGOCYTOSIS; PLEURA EFFUSION; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOCYTOPENIA; TUMOR CELL DESTRUCTION; TUMOR IMMUNITY; UNSPECIFIED SIDE EFFECT; VACCINE PRODUCTION; VASODILATATION; VITILIGO;

ANTIBODIES, MONOCLONAL; ANTIGEN-PRESENTING CELLS; ANTIGENS, NEOPLASM; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY; NEOPLASMS; T-LYMPHOCYTES;

EID: 80051493045     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.11.33     Document Type: Review

References (143)

1. Reff ME, Carner K, Chambers KS et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83(2), 435-445 (1994). (Pubitemid 24030569)
2. Glennie MJ, French RR, Cragg MS, Taylor R P. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol. Immunol. 44(16), 3823-3837 (2007). (Pubitemid 47332625)
3. Pescovitz MD. Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action. Am. J. Transplant. 6(5 Pt 1), 859-866 (2006). (Pubitemid 44356635)
4. Barok M, Isola J, Palyi-Krekk Z et al. Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol. Cancer Ther. 6(7), 2065-2072 (2007). (Pubitemid 47052497)
5. Carter P, Presta L, Gorman CM et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl Acad. Sci. USA 89(10), 4285-4289 (1992).
6. Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N. Engl. J. Med. 357(1), 39-51 (2007). (Pubitemid 47026733)
7. Izumi Y, Xu L, di Tomaso E, Fukumura D, Jain RK. Tumour biology: Herceptin acts as an anti-angiogenic cocktail. Nature 416(6878), 279-280 (2002). (Pubitemid 34260234)
8. Alinari L, Lapalombella R, Andritsos L, Baiocchi RA, Lin TS, Byrd JC. Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia. Oncogene 26(25), 3644-3653 (2007). (Pubitemid 46842714)
9. Hale G, Dyer MJ, Clark MR et al. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet 2(8625), 1394-1399 (1988). (Pubitemid 19004485)
10. Ravandi F, O'Brien S. Alemtuzumab. Expert Rev. Anticancer Ther. 5(1), 39-51 (2005). (Pubitemid 40287435)
11. Galizia G, Lieto E, De Vita F et al. Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer. Oncogene 26(25), 3654-3660 (2007). (Pubitemid 46842715)
12. Kawaguchi Y, Kono K, Mimura K, Sugai H, Akaike H, Fujii H. Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma. Int. J. Cancer 120(4), 781-787 (2007). (Pubitemid 46175397)
13. Mendelsohn J. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin. Cancer Res. 3(12 Pt 2), 2703-2707 (1997). (Pubitemid 28133130)
14. Kim KJ, Li B, Winer J et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362(6423), 841-844 (1993). (Pubitemid 23132159)
15. Kramer I, Lipp HP. Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer. J. Clin. Pharm Ther. 32(1), 1-14 (2007). (Pubitemid 46213936)
16. Presta LG, Chen H, O'Connor SJ et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57(20), 4593-4599 (1997). (Pubitemid 27441066)
17. Cohenuram M, Saif MW. Panitumumab the frst fully human monoclonal antibody: from the bench to the clinic. Anticancer Drugs 18(1), 7-15 (2007). (Pubitemid 44949790)
18. Jakobovits A, Amado RG, Yang X, Roskos L, Schwab G. From XenoMouse technology to panitumumab, the frst fully human antibody product from transgenic mice. Nat. Biotechnol. 25(10), 1134-1143 (2007). (Pubitemid 47542248)
19. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med. 6(4), 443-446 (2000). (Pubitemid 30208162)
20. Fan Z, Masui H, Altas I, Mendelsohn J. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res. 53(18), 4322-4328 (1993). (Pubitemid 24146785)
21. Desjarlais JR, Lazar GA, Zhukovsky EA, Chu SY. Optimizing engagement of the immune system by anti-tumor antibodies: an engineers perspective. Drug Discov. Today 12(21-22), 898-910 (2007). (Pubitemid 350052671)
22. Clynes R. Antitumor antibodies in the treatment of cancer: Fc receptors link opsonic antibody with cellular immunity. Hematol. Oncol. Clin. North Am. 20(3), 585-612 (2006). (Pubitemid 43817439)
23. Nimmerjahn F, Ravetch JV. Fcγ receptors: old friends and new family members. Immunity 24(1), 19-28 (2006). (Pubitemid 43077197)
24. Klos A, Tenner AJ, Johswich KO, Ager RR, Reis ES, Kohl J. The role of the anaphylatoxins in health and disease. Mol. Immunol. 46(14), 2753-2766 (2009).
25. Regnault A, Lankar D, Lacabanne V et al Fcγ receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J. Exp. Med. 189(2), 371-380 (1999). (Pubitemid 29063258)
26. Boruchov AM, Heller G, Veri MC, Bonvini E, Ravetch JV, Young JW. Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. J. Clin. Invest. 115(10), 2914-2923 (2005). (Pubitemid 41434419)
27. Schakel K, Mayer E, Federle C, Schmitz M, Riethmuller G, Rieber EP. A novel dendritic cell population in human blood: one-step immunomagnetic isolation by a specifc mAb (M-DC8) and in vitro priming of cytotoxic T lymphocytes. Eur. J. Immunol. 28(12), 4084-4093 (1998). (Pubitemid 28558638)
28. Abes R, Gelize E, Fridman WH, Teillaud JL. Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response. Blood 116(6), 926-934 (2010).
29. Selenko N, Majdic O, Jager U, Sillaber C, Stockl J, Knapp W. Cross-priming of cytotoxic T cells promoted by apoptosis-inducing tumor cell reactive antibodies? J. Clin. Immunol. 22(3), 124-130 (2002). (Pubitemid 34596935)
30. Taylor C, Hershman D, Shah N et al. Augmented HER-2 specifc immunity during treatment with trastuzumab and chemotherapy. Clin. Cancer Res. 13(17), 5133-5143 (2007). (Pubitemid 47502081)
31. + T-cell axis in patients with breast cancer. Br. J. Cancer 100(7), 1061-1067 (2009).
32. Park S, Jiang Z, Mortenson ED et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 18(2), 160-170).
33. Gilboa E. DC-based cancer vaccines. J. Clin. Invest. 117(5), 1195-1203 (2007). (Pubitemid 46718404)
34. Schadendorf D, Ugurel S, Schuler-Thurner B et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in frst-line treatment of patients with metastatic melanoma: a randomized Phase III trial of the DC study group of the DeCOG. Ann. Oncol. 17(4), 563-570 (2006).
35. Small EJ, Schellhammer PF, Higano CS et al. Placebo-controlled Phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol. 24(19), 3089-3094 (2006). (Pubitemid 46638945)
36. Dhodapkar KM, Kaufman JL, Ehlers M et al. Selective blockade of inhibitory Fcg receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells. Proc. Natl Acad. Sci. USA 102(8), 2910-2915 (2005). (Pubitemid 40299890)
37. Kalergis AM, Ravetch J V. Inducing tumor immunity through the selective engagement of activating Fcg receptors on dendritic cells. J. Exp. Med. 195(12), 1653-1659 (2002). (Pubitemid 34666079)
38. Akiyama K, Ebihara S, Yada A et al. Targeting apoptotic tumor cells to Fc g R provides effcient and versatile vaccination against tumors by dendritic cells. J. Immunol. 170(4), 1641-1648 (2003). (Pubitemid 36197377)
39. Rafq K, Bergtold A, Clynes R. Immune complex-mediated antigen presentation induces tumor immunity. J. Clin. Invest. 110(1), 71-79 (2002). (Pubitemid 34743467)
40. You Z, Huang X, Hester J, Toh HC, Chen SY. Targeting dendritic cells to enhance DNA vaccine potency. Cancer Res. 61(9), 3704-3711 (2001). (Pubitemid 32694983)
41. Qin H, Zhou C, Wang D et al. Specifc antitumor immune response induced by a novel DNA vaccine composed of multiple CTL and T helper cell epitopes of prostate cancer associated antigens. Immunol. Lett. 99(1), 85-93 (2005). (Pubitemid 40718938)
42. Harbers SO, Crocker A, Catalano G et al. Antibody-enhanced cross-presentation of self antigen breaks T cell tolerance. J. Clin. Invest. 117(5), 1361-1369 (2007). (Pubitemid 46718424)
43. Kim PS, Armstrong TD, Song H et al. Antibody association with HER-2/neu-targeted vaccine enhances CD8 T cell responses in mice through Fc-mediated activation of DCs. J. Clin. Invest. 118(5), 1700-1711 (2008). (Pubitemid 351632374)
44. Saenger YM, Li Y, Chiou KC et al. Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma. Cancer Res. 68(23), 9884-9891 (2008).
45. Weiner LM, Dhodapkar MV, Ferrone S. Monoclonal antibodies for cancer immunotherapy. Lancet 373(9668), 1033-1040 (2009).
46. Pfsterer J, du Bois A, Sehouli J et al. The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A Phase I trial of the AGO-OVAR. Ann. Oncol. 17(10), 1568-1577 (2006). (Pubitemid 44548850)
47. Reinartz S, Kohler S, Schlebusch H et al. Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (Phase Ib/II). Clin. Cancer Res. 10(5), 1580-1587 (2004). (Pubitemid 38435546)
48. Sabbatini P, Dupont J, Aghajanian C et al. Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clin. Cancer Res. 12(18), 5503-5510 (2006). (Pubitemid 44497267)
49. Wagner U, Kohler S, Reinartz S et al. Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. See The biology behind: K. A. Foon and M. Bhattacharya-Chatterjee, Are solid tumor anti-idiotype vaccines ready for prime time? Clin. Cancer Res. 7:1112-1115, 2001.
50. Clin. Cancer Res. 7(5), 1154-1162 (2001).
51. Diaz Y, Gonzalez A, Lopez A, Perez R, Vazquez AM, Montero E. Anti-ganglioside anti-idiotypic monoclonal antibody-based cancer vaccine induces apoptosis and antiangiogenic effect in a metastatic lung carcinoma. Cancer Immunol. Immunother. 58(7), 1117-1128 (2009).
52. Amin S, Robins RA, Maxwell-Armstrong CA, Scholefeld JH, Durrant LG. Vaccine-induced apoptosis: a novel clinical trial end point? Cancer Res. 60(12), 3132-3136 (2000).
53. Pritchard-Jones K, Wilton C, Spendlove I et al. Immune responses to the 105AD7 human anti-idiotypic vaccine after intensive chemotherapy for osteosarcoma. 92(8), 1358-1365 (2005).
54. Ullenhag GJ, Mukherjee A, Watson NF, Al-Attar AH, Scholefeld JH, Durrant LG. Overexpression of FLIPL is an independent marker of poor prognosis in colorectal cancer patients. Clin. Cancer Res. 13(17), 5070-5075 (2007). (Pubitemid 47502072)
55. Ullenhag GJ, Spendlove I, Watson NF, Kallmeyer C, Pritchard-Jones K, Durrant LG. T-cell responses in osteosarcoma patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55. Clin. Immunol. 128(2), 148-154 (2008).
56. Billetta R, Hollingdale MR, Zanetti M. Immunogenicity of an engineered internal image antibody. Proc. Natl Acad. Sci. USA 88(11), 4713-4717 (1991). (Pubitemid 21914612)
57. Brumeanu TD, Swiggard WJ, Steinman RM, Bona CA, Zaghouani H. Effcient loading of identical viral peptide onto class II molecules by antigenized immunoglobulin and infuenza virus. J. Exp. Med. 178(5), 1795-1799 (1993). (Pubitemid 23318460)
58. Li S, Polonis V, Isobe H et al. Chimeric infuenza virus induces neutralizing antibodies and cytotoxic T cells against human immunodefciency virus type 1. J. Virol. 67(11), 6659-6666 (1993). (Pubitemid 23309133)
59. Kuzu Y, Kuzu H, Zaghouani H, Bona C. Priming of cytotoxic T lymphocytes at various stages of ontogeny with transfectoma cells expressing a chimeric Ig heavy chain gene bearing an infuenza virus nucleoprotein peptide. Int. Immunol. 5(10), 1301-1307 (1993). (Pubitemid 23308091)
60. Zaghouani H, Steinman R, Nonacs R, Shah H, Gerhard W, Bona C. Presentation of a viral T cell epitope expressed in the CDR3 region of a self immunoglobulin molecule. Science 259(5092), 224-227 (1993). (Pubitemid 23041798)
61. Bot A, Smith D, Phillips B, Bot S, Bona C, Zaghouani H. Immunologic control of tumors by in vivo Fc g receptor-targeted antigen loading in conjunction with double-stranded RNA-mediated immune modulation. J. Immunol. 176(3), 1363-1374 (2006). (Pubitemid 43134278)
62. Metheringham RL, Pudney VA, Gunn B, Towey M, Spendlove I, Durrant LG. Antibodies designed as effective cancer vaccines. MABs 1(1), 71-85 (2009).
63. + T cells. Eur. J. Immunol. 40(3), 899-910 (2010).
64. Fuller DH, Loudon P, Schmaljohn C. Preclinical and clinical progress of particle-mediated DNA vaccines for infectious diseases. Methods 40(1), 86-97 (2006). (Pubitemid 44419542)
65. + T cells. J. Immunol. 179(7), 4741-4753 (2007).
66. van Drunen Littel-van den Hurk S, Lawman Z, Wilson D et al. Electroporation enhances immune responses and protection induced by a bovine viral diarrhea virus DNA vaccine in newborn calves with maternal antibodies. Vaccine 28(39), 6445-6454 (2010).
67. Fredriksen AB, Sandlie I, Bogen B. DNA vaccines increase immunogenicity of idiotypic tumor antigen by targeting novel fusion proteins to antigen-presenting cells. Mol. Ther. 13(4), 776-785 (2006).
68. Tunheim G, Thompson KM, Fredriksen AB, Espevik T, Schjetne KW, Bogen B. Human receptors of innate immunity (CD 14, TLR2) are promising targets for novel recombinant immunoglobulin-based vaccine candidates. Vaccine 25(24), 4723-4734 (2007). (Pubitemid 46755452)
69. Hawiger D, Inaba K, Dorsett Y et al Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J. Exp. Med. 194(6), 769-779 (2001). (Pubitemid 32983013)
70. Mahnke K, Qian Y, Fondel S, Brueck J, Becker C, Enk AH. Targeting of antigens to activated dendritic cells in vivo cures metastatic melanoma in mice. Cancer Res. 65(15), 7007-7012 (2005). (Pubitemid 41060741)
71. + T cell immunity to mouse survivin. J. Immunol. 177(12), 8410-8421 (2006). (Pubitemid 44893803)
72. Idoyaga J, Cheong C, Suda K et al. Cutting edge: langerin/CD207 receptor on dendritic cells mediates effcient antigen presentation on MHC I and II products in vivo. J. Immunol. 180(6), 3647-3650 (2008).
73. Demangel C, Zhou J, Choo AB, Shoebridge G, Halliday GM, Britton WJ. Single chain antibody fragments for the selective targeting of antigens to dendritic cells. Mol. Immunol. 42(8), 979-985 (2005). (Pubitemid 40489023)
74. Nchinda G, Kuroiwa J, Oks M et al. The effcacy of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cells. J. Clin. Invest. 118(4), 1427-1436 (2008). (Pubitemid 351500436)
75. Grossmann C, Tenbusch M, Nchinda G et al. Enhancement of the priming effcacy of DNA vaccines encoding dendritic cell-targeted antigens by synergistic Toll-like receptor ligands. BMC Immunol. 10, 43 (2009).
76. Ramakrishna V, Treml JF, Vitale L et al. Mannose receptor targeting of tumor antigen pmel17 to human dendritic cells directs anti-melanoma T cell responses via multiple HLA molecules. J. Immunol. 172(5), 2845-2852 (2004). (Pubitemid 38263669)
77. He LZ, Crocker A, Lee J et al. Antigenic targeting of the human mannose receptor induces tumor immunity. J. Immunol. 178(10), 6259-6267 (2007). (Pubitemid 46717409)
78. Luhder F, Huang Y, Dennehy KM et al. Topological requirements and signaling properties of T cell-activating, anti-CD28 antibody superagonists. J. Exp. Med. 197(8), 955-966 (2003). (Pubitemid 36523193)
79. Rodriguez-Palmero M, Hara T, Thumbs A, Hunig T. Triggering of T cell proliferation through CD28 induces GATA-3 and promotes T helper type 2 differentiation in vitro and in vivo. Eur. J. Immunol. 29(12), 3914-3924 (1999).
80. Suntharalingam G, Perry MR, Ward S et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 355(10), 1018-1028 (2006). (Pubitemid 44343545)
81. Alegre ML, Noel PJ, Eisfelder BJ et al. Regulation of surface and intracellular expression of CTLA4 on mouse T cells. J. Immunol. 157(11), 4762-4770 (1996). (Pubitemid 126449549)
82. Linsley PS, Bradshaw J, Greene J, Peach R, Bennett KL, Mittler RS. Intracellular traffcking of CTLA-4 and focal localization towards sites of TCR engagement. Immunity 4(6), 535-543 (1996). (Pubitemid 26233307)
83. van der Merwe PA, Bodian DL, Daenke S, Linsley P, Davis SJ. CD80 (B7-1) binds both CD28 and CTLA-4 with a low affnity and very fast kinetics. J. Exp. Med. 185(3), 393-403 (1997). (Pubitemid 27078358)
84. + T cells. Eur. J. Immunol. 28(10), 3137-3143 (1998). (Pubitemid 28470259)
85. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3(5), 541-547 (1995).
86. Waterhouse P, Penninger JM, Timms E et al. Lymphoproliferative disorders with early lethality in mice defcient in CTLA-4. Science 270(5238), 985-988 (1995).
87. Morse MA. Technology evaluation: ipilimumab, Medarex/Bristol-Myers Squibb. Curr. Opin. Mol. Ther. 7(6), 588-597 (2005). (Pubitemid 41764000)
88. + regulatory T cells abrogates their function in vivo. J. Immunol. 177(7), 4376-4383 (2006). (Pubitemid 44469766)
89. Sansom DM, Walker LS. The role of CD28 and cytotoxic T-lymphocyte antigen-4 (CTLA-4) in regulatory T-cell biology. Immunol. Rev. 212, 131-148 (2006). (Pubitemid 44116705)
90. + regulatory T Cells cons tit utively expressing cytotoxic T lymphocyte-associated antigen 4. J. Exp. Med. 192(2), 303-309 (2000). (Pubitemid 30470313)
91. Grohmann U, Orabona C, Fallarino F et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat. Immunol. 3(11), 1097-1101 (2002). (Pubitemid 35363664)
92. Ying H, Yang L, Qiao G et al. Cutting edge: CTLA-4-B7 interaction suppresses Th17 cell differentiation. J. Immunol. 185(3), 1375-1378 (2010).
93. Kwon ED, Hurwitz AA, Foster BA et al. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc. Natl Acad. Sci. USA 94(15), 8099-8103 (1997). (Pubitemid 27343783)
94. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271(5256), 1734-1736 (1996). (Pubitemid 26102823)
95. Yang YF, Zou JP, Mu J et al. Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages. Cancer Res. 57(18), 4036-4041 (1997). (Pubitemid 27427694)
96. +) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med. 194(6), 823-832 (2001). (Pubitemid 32983017)
97. Hurwitz AA, Foster BA, Kwon ED et al. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res. 60(9), 2444-2448 (2000). (Pubitemid 30262435)
98. Hurwitz AA, Yu TF, Leach DR, Allison JP. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc. Natl Acad. Sci. USA 95(17), 10067-10071 (1998). (Pubitemid 28415295)
99. van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J. Exp. Med. 190(3), 355-366 (1999). (Pubitemid 29374833)
100. Quezada SA, Peggs KS, Curran MA, Allison JP. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J. Clin. Invest. 116(7), 1935-1945 (2006). (Pubitemid 44033317)
101. +) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J. Exp. Med. 207(3), 637-650 (2010).
102. Camacho LH, Antonia S, Sosman J et al. Phase I/II trial of tremelimumab in patients with metastatic melanoma. J. Clin. Oncol. 27(7), 1075-1081 (2009).
103. Robert C, Ghiringhelli F. What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma? Oncologist 14(8), 848-861 (2009).
104. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl. J. Med. 363(8), 711-723 (2010).
105. Maker AV, Attia P, Rosenberg SA. Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J. Immunol. 175(11), 7746-7754 (2005). (Pubitemid 41713475)
106. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26, 677-704 (2008). (Pubitemid 351600389)
107. Nishimura H, Okazaki T, Tanaka Y et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-defcient mice. Science 291(5502), 319-322 (2001). (Pubitemid 32096320)
108. Nishimura T, Iwakabe K, Sekimoto M et al. Distinct role of antigen-specifc T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J. Exp. Med. 190(5), 617-627 (1999). (Pubitemid 29428646)
109. + T lymphocytes are prognostic factors of human ovarian cancer. Proc. Natl Acad. Sci. USA 104(9), 3360-3365 (2007). (Pubitemid 46364164)
110. Thompson RH, Kuntz SM, Leibovich BC et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 66(7), 3381-3385 (2006).
111. Blank C, Brown I, Marks R, Nishimura H, Honjo T, Gajewski TF. Absence of programmed death receptor 1 alters thymic development and enhances generation of CD4/CD8 double-negative TCR-transgenic T cells. J. Immunol. 171(9), 4574-4581 (2003). (Pubitemid 37310573)
112. + T cell responses to antigen in lymph nodes and tissues. J. Immunol. 179(8), 5064-5070 (2007).
113. Ansari MJ, Salama AD, Chitnis T et al. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J. Exp. Med. 198(1), 63-69 (2003). (Pubitemid 36870186)
114. Keir ME, Liang SC, Guleria I et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J. Exp. Med. 203(4), 883-895 (2006).
115. + T cell tolerance through PD-1 and CTLA-4. Nat. Immunol. 6(3), 280-286 (2005). (Pubitemid 41724765)
116. Francisco LM, Salinas VH, Brown KE et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J. Exp. Med. 206(13), 3015-3029 (2009).
117. Latchman Y, Wood CR, Chernova T et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol. 2(3), 261-268 (2001). (Pubitemid 33706004)
118. Parry RV, Chemnitz JM, Frauwirth KA et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol. Cell Biol. 25(21), 9543-9553 (2005). (Pubitemid 41507854)
119. Barber DL, Wherry EJ, Masopust D et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439(7077), 682-687 (2006). (Pubitemid 43237609)
120. + T cell expansion in melanoma patients. J. Immunol. 182(9), 5240-5249 (2009).
121. Wong RM, Scotland RR, Lau RL et al. Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specifc CTLs. Int. Immunol. 19(10), 1223-1234 (2007). (Pubitemid 47500645)
122. + T cells. Cancer Res. 64(3), 1140-1145 (2004). (Pubitemid 38176921)
123. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl Acad. Sci. USA 99(19), 12293-12297 (2002).
124. Strome SE, Dong H, Tamura H et al. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res. 63(19), 6501-6505 (2003). (Pubitemid 37255203)
125. Brahmer JR, Drake CG, Wollner I et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28(19), 3167-3175 (2010).
126. Brahmer JR, Toplian SL, Powderly J et al. Phase II experience with MDX-1106 (ONO-4538), an anti-PD-1/PD-L1 monoclonal antibody, in patients with selected refractory or relapsed malignancies. J. Clin. Oncol. 27 (2008) (Abstract 3015).
127. Berger R, Rotem-Yehudar R, Slama G et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin. Cancer Res. 14(10), 3044-3051 (2008).
128. +) cytotoxic T lymphocyte priming capacity upon activation by T helper cell-independent or-dependent stimuli. J. Exp. Med. 192(1), 145-150 (2000). (Pubitemid 30470816)
129. Diehl L, den Boer AT, Schoenberger SP et al. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine effcacy. Nat. Med. 5(7), 774-779 (1999). (Pubitemid 29318611)
130. + CTL to cause tumor eradication. J. Immunol. 173(11), 6753-6759 (2004). (Pubitemid 39541061)
131. Vonderheide RH, Flaherty KT, Khalil M et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J. Clin. Oncol. 25(7), 876-883 (2007). (Pubitemid 350002889)
132. Advani R, Forero-Torres A, Furman RR et al. Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma. J. Clin. Oncol. 27(26), 4371-4377 (2009).
133. Weinberg AD, Evans DE, Thalhofer C, Shi T, Prell RA. The generation of T cell memory: a review describing the molecular and cellular events following OX40 (CD134) engagement. J. Leukoc. Biol. 75(6), 962-972 (2004). (Pubitemid 38720636)
134. +) T cell mobilization/memory development and humoral immunity: comparison of aOX-40 with aCTLA-4. J. Immunol. 167(12), 6804-6811 (2001). (Pubitemid 33144171)
135. Kjaergaard J, Tanaka J, Kim JA, Rothchild K, Weinberg A, Shu S. Therapeutic effcacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth. Cancer Res. 60(19), 5514-5521 (2000).
136. Redmond WL, Gough MJ, Charbonneau B, Ratliff TL, Weinberg AD. Defects in the acquisition of CD8 T cell effector function after priming with tumor or soluble antigen can be overcome by the addition of an OX40 agonist. J. Immunol. 179(11), 7244-7253 (2007).
137. Weinberg AD, Rivera MM, Prell R et al. Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J. Immunol. 164(4), 2160-2169 (2000). (Pubitemid 30108775)
138. Kovacsovics-Bankowski M WE, Floyd k et al. Increased CD4 and CD8 memory T cell proliferation following anti-OX40 administration to cancer patients: immunologic assessment of a Phase I clinical trial. Curr. Opin. Oncol. 23(2), 163-169 (2009).
139. Alderson MR, Smith CA, Tough TW et al. Molecular and biological characterization of human 4-1BB and its ligand. Eur. J. Immunol. 24(9), 2219-2227 (1994). (Pubitemid 24276559)
140. Gramaglia I, Cooper D, Miner KT, Kwon BS, Croft M. Co-stimulation of antigen-specifc CD4 T cells by 4-1BB ligand. Eur. J. Immunol. 30(2), 392-402 (2000). (Pubitemid 30098831)
141. + T cell proliferation and lead to the amplifcation in vivo of cytotoxic T cell responses. J. Exp. Med. 186(1), 47-55 (1997). (Pubitemid 27304846)
142. Miller RE, Jones J, Le T et al. 4-1BB-specifc monoclonal antibody promotes the generation of tumor-specifc immune responses by direct activation of CD8 T cells in a CD40-dependent manner. J. Immunol. 169(4), 1792-1800 (2002). (Pubitemid 34857639)
143. Sznol M, Hodi FS, Margolin K et al. Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer. J. Clin. Oncol. 26(Suppl.) (2008) (Abstract 3007).